Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Oct 18:6:139.
doi: 10.3389/fcell.2018.00139. eCollection 2018.

Stem/Progenitor Cells and Their Therapeutic Application in Cardiovascular Disease

Yuning Hou  1 , Chunying Li  1
Affiliations
Review

Stem/Progenitor Cells and Their Therapeutic Application in Cardiovascular Disease

Yuning Hou et al. Front Cell Dev Biol. .

Abstract

Cardiovascular disease is the leading cause of death in the world. The stem/progenitor cell-based therapy has emerged as a promising approach for the treatment of a variety of cardiovascular diseases including myocardial infarction, stroke, peripheral arterial disease, and diabetes. An increasing number of evidence has shown that stem/progenitor cell transplantation could replenish damaged cells, improve cardiac and vascular functions, and repair injured tissues in many pre-clinical studies and clinical trials. In this review, we have outlined the major types of stem/progenitor cells, and summarized the studies in applying these cells, especially endothelial stem/progenitor cells and their derivatives, in the treatment of cardiovascular disease. Here the strategies used to improve the stem/progenitor cell-based therapies in cardiovascular disease and the challenges with these therapies in clinical applications are also reviewed.

Keywords: cardiovascular disease; cell therapy; endothelial progenitor cells; progenitor cells; stem cells.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ambasta R. K., Kohli H., Kumar P. (2017). Multiple therapeutic effect of endothelial progenitor cell regulated by drugs in diabetes and diabetes related disorder. J. Transl. Med. 15:185. 10.1186/s12967-017-1280-y - DOI - PMC - PubMed
    1. Asahara T., Kawamoto A., Masuda H. (2011). Concise review: circulating endothelial progenitor cells for vascular medicine. Stem Cells 29 1650–1655. 10.1002/stem.745 - DOI - PubMed
    1. Asahara T., Masuda H., Takahashi T., Kalka C., Pastore C., Silver M., et al. (1999). Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ. Res. 85 221–228. 10.1161/01.RES.85.3.221 - DOI - PubMed
    1. Asahara T., Murohara T., Sullivan A., Silver M., Van Der Zee R., Li T., et al. (1997). Isolation of putative progenitor endothelial cells for angiogenesis. Science 275 964–967. 10.1126/science.275.5302.964 - DOI - PubMed
    1. Bianconi V., Fallarino F., Mannarino M. R., Bagaglia F., Kararoudi M. N., Aragona C. O., et al. (2017). Autologous cell therapy for vascular regeneration: the role of proangiogenic cells. Curr. Med. Chem. [Epub ahead of print]. 10.2174/0929867324666171012111603 - DOI - PubMed

LinkOut - more resources